IP Library › Granted Patent US 12,186,342
Granted Patent B2
US 12,186,342 · App. 16/335,653 · Granted Jan 7, 2025

Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha

Inventor: Karin Gaensler (Oakland, CA)
Assignee: The Regents of the University of California
A61K35/13A61K38/2086A61K39/0011A61P35/02C12N5/0693C12N5/0694C12N5/10A61K35/15A61K2039/5152A61K2039/5156A61K2039/804C12N13/00C12N2501/2315
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,342
App. No.
16/335,653
Granted
Jan 7, 2025
Kind
B2
Abstract

Provided herein, inter alia, are cell media compositions and whole cell vaccines comprising recombinant cells expressing IL-15, IL-15Rα, and CD80 capable of treating and preventing relapse in individuals diagnosed with or thought to have leukemia as well as methods for using the same.

Claims (28)

1. A cell media composition comprising:

(1) recombinant leukemia cells comprising a multicistronic nucleic acid molecule comprising nucleic acid sequences encoding IL-15, IL-15Rα, and CD80,

wherein the sequences encoding IL-15, IL-15Rα, and CD80 are linked to one another via a self-cleaving peptide sequence,

wherein the recombinant leukemia cells are capable of: (i) expressing IL-15, IL-15Rα, and CD80 on the cell surface; and (ii) secreting IL-15 from said cells into the media; and

(2) IL-15 secreted from the recombinant leukemia cells,

wherein the concentration of secreted IL-15 in the cell media composition is about 150-400 ng/mL.

2. The media composition of claim 1 , wherein the recombinant leukemia cells are acute myelogenous leukemia (AML) cells.

3. The media composition of claim 1 , wherein the recombinant leukemia cell are derived from an individual diagnosed with or thought to have leukemia.

4. The media composition of claim 3 , wherein the individual is in remission for AML.

5. The media composition of claim 4 , wherein the individual is with AML in remission with minimal residual disease (MRD).

6. The media composition of claim 1 , wherein the composition is irradiated.

7. The media composition of claim 1 , wherein the recombinant leukemia cells are created by transduction with a vector comprising the multicistronic nucleic acid molecule.

8. A method of stimulating an immune response in an individual with acute myelogenous leukemia (AML) in remission with persistent minimal residual disease (MRD), comprising administering an effective amount of a cell media composition according to claim 1 .

9. The method of claim 8 , wherein the recombinant leukemia cells are autologous cells derived from the individual.

10. The method of claim 8 , wherein the composition is formulated into a whole-cell vaccine.

11. The method of claim 8 , wherein the method

(i) stimulates the proliferation of one or more of CD3+CD8 + T cells, CD3 + CD4 + T cells, memory CD8 + T cells, NK cells, and NKT cells relative to the proliferation of one or more of these cells in individuals who have not been administered the composition;

(ii) stimulates the proliferation of CD3+CD8+ T cells and/or CD3+CD4+ T cells up to five fold relative to the proliferation of one or more of these cells in individuals who have not been administered the composition;

(iii) stimulates increased production of interferon gamma (IFNγ) relative to the production of IFNγ in individuals who have not been administered the composition; and/or

(iv) prevents relapse of AML relative to the rate of relapse of AML in individuals who have not been administered the composition.

12. The method of claim 8 , wherein the individual is a human.

13. The method of claim 8 , wherein the recombinant leukemia cells are acute myelogenous leukemia cells.

14. The method of claim 8 , wherein the individual is about 60 years of age or older.

15. The method of claim 8 , wherein the composition is irradiated.

16. The method of claim 8 , wherein the recombinant leukemia cells are created by transduction with a vector comprising the multicistronic nucleic acid molecule.

17. The method of claim 16 , wherein the vector is a tri-cistronic vector.

18. The method of claim 8 , wherein the method results in increased progression free survival of the individual relative to the rate of progression free survival in individuals with AML who have not been administered the vaccine.

19. A method of treating acute myelogenous leukemia (AML) in remission with persistent minimal residual disease comprising administering to a patient in need thereof an effective amount of a cell media composition according to claim 1 .

Continuity (2)
Provisional Application 62398980 · Sep 23, 2016
Related Publication 20200179447A1 · Jun 11, 2020
References Cited (83)
US 9278128B2 · Weiner et al. · 2016 [cited by applicant]
US 20020018767A1 · Lee et al. · 2002 [cited by applicant]
US 20060165668A1 · Liu et al. · 2006 [cited by applicant]
US 20070160578A1 · Waldmann et al. · 2007 [cited by applicant]
US 20140205560A1 · Wong et al. · 2014 [cited by applicant]
US 20160102128A1 · Felber · 2016 [cited by examiner]
US 20170020963A1 · Qu · 2017 [cited by examiner]
Chan et al. (2005) Mol. Ther., vol. 11(1), 120-131. [cited by examiner]
Morris et al. (2014) Gene Therapy, vol. 21, 393-401. [cited by examiner]
Klebanoff et al. (2004) PNAS, vol. 101(7), 1969-1974. [cited by examiner]
Dunussi-joannopoulos et al. (2001) Leukemia and Lymphoma, vol. 41(5-6), 482-492. [cited by examiner]
Ingram et al. (2009) Brit. J. Haematol., vol. 145, 749-760. [cited by examiner]
Wen et al. (2001) Cancer Gene Therapy, vol. 8(5), 361-370. [cited by examiner]
Anderson, D.M. et al. (Dec. 15, 1995). “Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes,” [cited by applicant]
Bergamaschi, C. et al. (Feb. 15, 2008, e-published Nov. 30, 2007). “Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity,” [cited by applicant]
Bergamaschi, C. et al. (Sep. 1, 2009). “Secretion and biological activity of short signal peptide IL-15 is chaperoned by IL-15 receptor alpha in vivo,” [cited by applicant]
Bergamaschi, C. et al. (Jul. 5, 2012, Apr. 10, 2012). “Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum,” [cited by applicant]
Berger, C. et al. (Mar. 15, 2006, e-published Nov. 10, 2005). “Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic … [cited by applicant]
Bessard, A. et al. (Sep. 2009, e-published Sep. 1, 2009). “High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer,” [cited by applicant]
Borrello, I.M. et al. (Aug. 7, 2009, e-published Jun. 25, 2009). “Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT… [cited by applicant]
Boyer, M.W. et al. (May 1, 1997). “The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties,” [cited by applicant]
Carlyle, J.R. et al. (Jun. 15, 2006). “Molecular and genetic basis for strain-dependent NK1.1 alloreactivity of mouse NK cells,” [cited by applicant]
Chan, L. et al. (Jan. 2005). “IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML,” [cited by applicant]
Chertova, E. et al. (Jun. 21, 2013, e-published May 6, 2013). “Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer,” [cited by applicant]
Ciernik, I.F. et al. (Oct. 1, 1999). “Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope,” [cited by applicant]
Comes, A. et al. (Jul. 2002). “IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice,” [cited by applicant]
Cook, G.J. et al. (Jun. 2013). “Animal models of leukemia: any closer to the real thing?” [cited by applicant]
Daley, G.Q. et al. (Feb. 16, 1990). “Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome,” [cited by applicant]
Dicarlo, E. et al. (Sep. 15, 2000). “The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement,” [cited by applicant]
Distasi, A. et al. (Feb. 4, 2015). “Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies,” [cited by applicant]
Dombret, H. et al. (Jan. 7, 2016, e-published Dec. 10, 2015). “An update of current treatments for adult acute myeloid leukemia,” [cited by applicant]
Donnelly, M.L. et al. (May 2001). “The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences,” [cited by applicant]
Dranoff, G. et al. (Apr. 15, 1993). “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunit… [cited by applicant]
Dubois, S. et al. (Nov. 2002). “IL-15Rα recycles and presents IL-15 In trans to neighboring cells,” [cited by applicant]
Falahati, R. et al. (Nov. 2012, e-published Aug. 7, 2012). “Chemoselection of allogeneic HSC after murine neonatal transplantation without myeloablation or post-transplant immunosuppression,” [cited by applicant]
Gillgrass, A. et al. (Dec. 15, 2014, e-published Oct. 29, 2014). “The absence or overexpression of IL-15 drastically alters breast cancer metastasis via effects on NK cells, CD4 T cells, and macrophages,” [cited by applicant]
Giorda, R. et al. (Sep. 15, 1992). “Genomic structure and strain-specific expression of the natural killer cell receptor NKR-P1,” [cited by applicant]
Gravekamp, C. et al. (Aug. 2011, e-published Jul. 18, 2011). “The impact of aging on cancer vaccination,” [cited by applicant]
Grosso, D.A. et al. (Aug. 15, 2015, e-published Jun. 10, 2015). “Immunotherapy in acute myeloid leukemia,” Cancer 121(16):2689-2704. [cited by applicant]
Hadrup, S.R. et al. (Feb. 15, 2006). “Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in… [cited by applicant]
Hardwick, N. et al. (Mar. 2010, e-published Aug. 27, 2009). “Lytic activity against primary AML cells is stimulated in vitro by an autologous whole cell vaccine expressing IL-2 and CD80,” [cited by applicant]
Hasan, A.N et al. (Nov. 2016, e-published Aug. 31, 2016). “Soluble and membrane-bound interleukin (IL)-15 Rα/IL-15 complexes mediate proliferation of high-avidity central memory CD8+ T cells for adoptive immunotherapy o… [cited by applicant]
Hong, E. et al. (Apr. 22, 2016, e-published Dec. 30, 2015). “Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity,” [cited by applicant]
Hu, J. et al. (Jul. 1, 2014, e-published Jun. 2, 2014). “Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response,” [cited by applicant]
Ingram, W. et al. (Jun. 2009, e-published Apr. 20, 2009). “Human CD80/IL2 lentivirus-transduced acute myeloid leukaemia (AML) cells promote natural killer (NK) cell activation and cytolytic activity: implications for a … [cited by applicant]
International Search Report mailed on Dec. 11, 2017 for PCT Application No. PCT/US2017/053313, Sep. 25, 2017, 3 pages. [cited by applicant]
Jalah, R. et al. (Dec. 2007). “Efficient systemic expression of bioactive IL-15 in mice upon delivery of optimized DNA expression plasmids,” [cited by applicant]
Kim, J.H. et al. (2011, e-published Apr. 29, 2011). “High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice,” [cited by applicant]
Kishida, T. et al. (Nov. 2003). “Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic me… [cited by applicant]
Kowalczyk, A. et al. (Sep. 2007). “Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery,” [cited by applicant]
Koya, R.C. et al. (Sep. 2002 _. “Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimula… [cited by applicant]
Matulonis, U. et al. (Oct. 1993). “Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line,” [cited by applicant]
McGavin, J.K. et al. (2001). “Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients,” [cited by applicant]
Mehta, R.S. et al. (Feb-Mar. 2016). “Generating Peripheral Blood Derived Lymphocytes Reacting Against Autologous Primary AML Blasts,” [cited by applicant]
Mocchegiani, E. et al. (Aug. 2004). “NK and NKT cell functions in immunosenescence,” [cited by applicant]
Mortier, E. et al. (May 12, 2008, e-published May 5, 2008). “IL-15Rachaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation,” [cited by applicant]
Nishikado, H. et al. (May 15, 2011 e-published Apr. 13, 2011). “NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo,” [cited by applicant]
Plebanski, M. et al. (Jun. 2010). “Methods to measure T-cell responses,” [cited by applicant]
Posnett, D.M. et al. (Feb. 1, 1994). “Clonal populations of T cells in normal elderly humans: the T cell equivalent to benign monoclonal gammapathy,” [cited by applicant]
Rashidi, A. et al. (2016, e-published Feb. 6, 2016). “Antigen-specific immunotherapy for acute myeloid leukemia: where are we now, and where do we go from here?” [cited by applicant]
Rivas, C. et al. (May 2001). “BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir,” [cited by applicant]
Romano, E. et al. (May 31, 2012, e-published Apr. 17, 2012). “Human Langerhans cells use an IL-15R-α/IL-15/pSTAT5-dependent mechanism to break T-cell tolerance against the self-differentiation tumor antigen WT1,” [cited by applicant]
Rosati, M. et al. (Sep. 19, 2008, e-published Apr. 21, 2008). “Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation,” [cited by applicant]
Sandau, M.M. et al. (Dec. 1, 2004). “Cutting edge: transpresentation of IL-15 by bone marrow-derived cells necessitates expression of IL-15 and IL-15R α by the same cells,” [cited by applicant]
Sasine, J.P. et al. (Jan. 2015, e-published Jul. 16, 2014). “Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials,” Blood Rev 29(1):1… [cited by applicant]
Slifka, M.K. et al. (Feb. 15, 2000). NK markers are expressed on a high percentage of virus-specific CD8+ and CD4+ T cells, [cited by applicant]
Stitz, L. et al. (Jun. 5, 1986). “Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities,” [cited by applicant]
Stoklasek, T.A. et al. (Nov. 1, 2006). “Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo,” [cited by applicant]
Sun, H. et al. (February-Mar. 2016, e-published Jan. 8, 2016). “IL-15/sIL-15Rα gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys,” [cited by applicant]
Sweeney, C.L. et al. (Mar. 2002). “Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia,” [cited by applicant]
Sweeney, C.L. et al. (Mar. 15, 2003). “Trimetrexate inhibits progression of the murine 32Dp210 model of chronic myeloid leukemia in animals expressing drug-resistant dihydrofolate reductase,” [cited by applicant]
Teague, R.M. et al. (Aug. 27, 2013). “Immune evasion in acute myeloid leukemia: current concepts and future directions,” [cited by applicant]
Vallera, D.A. et al. (Sep. 1999). “Targeting myeloid leukemia with a DT [cited by applicant]
Vandenbergh, J. et al. (Dec. 29, 2015). “Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity,” [cited by applicant]
Varma, T.K. et al. (Sep. 2001). “Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin-tolerant mice,” [cited by applicant]
Waldmann, T.A. et al. (May 5, 2011, e-published Mar. 8, 2011). “Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques,” [cited by applicant]
Waldmann, T.A. et al. (Mar. 2015). “The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy,” Cancer Immunol Res 3(3):219-227. [cited by applicant]
Written Opinion mailed on Dec. 11, 2017 for PCT Application No. PCT/US2017/053313, Sep. 25, 2017, 6 pages. [cited by applicant]
Xu, W. et al. (May 15, 2013, e-published May 3, 2013). “Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myelo… [cited by applicant]
Zhang, M. et al. (Jun. 15, 2012, e-published May 16, 2012). “Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2… [cited by applicant]
Brentjens, R.J. et al. (Mar. 2003, e-published Feb. 10, 2003). “Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15,” [cited by applicant]
Extended European Search Report mailed on May 29, 2020, for EP Patent Application No. 17854094.4, 10 pages. [cited by applicant]
Hasan, A.N. et al. (Aug. 15, 2009, e-published Jul. 27, 2009). “A panel of artificial APCs expressing prevalent HLA alleles permits generation of cytotoxic T cells specific for both dominant and subdominant viral epitop… [cited by applicant]